Publications

Blood-based Proteomic Profiling Identifies OSMR as a Novel Biomarker

Product:

Topic:

Disease Area:

Sample Type:

Topic/Product:

Disease Area:

Sample Type:

Background

Risk stratification in acute myeloid leukemia (AML) is critical to tailor timely induction therapy. The most widely utilized risk stratification approach is the European LeukemiaNet (ELN) that usually requires bone marrow biopsy and genomic testing. Inflammation is increasingly recognized as a critical factor in AML. Novel biomarkers from robust blood-based tests are needed to accurately and efficiently risk stratify patients with newly diagnosed AML.

Methods

— Inflammatory proteome was evaluated through blood-based proteomic profiling of 251 soluble inflammatory proteins using NUcleic acid Linked Immuno-Sandwich Assay (NULISA), a proximity-ligation assay based on NGS or PCR allowing attomolar (10-18) detection in 543 newly diagnosed AML patients
— Multivariable cox models with L1 regularization were used to test the independent
prognostic ability. A seven-protein prognostic score (Leukemia Inflammatory Risk Score, LIRS) was developed
— Model performance was assessed by cumulative concordance index (C-index) and time-dependent area under the curve (tdAUC).
— Findings were validated in internal and external cohorts, including a prospective cohort of newly diagnosed AML patients.

Authors & Affiliations

HA Abbas1, B Wang1, J Marvin-Peek1, B Yuan1, A Garza1, J Root1, A Arruda2, Y Liu1, CD DiNardo1, TM Kadia1, NG Daver1, PL Lorenzi1, K Sasaki1, S Kornblau1, MD Minden2, F Ravandi1, HM Kantarjian1, PK Reville1

1The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2Princess Margaret Cancer Centre, Toronto, Ontario, Canada

Steve Williams, MD, PhD

CSO

Dr. Willams serves as the company’s Chief Scientific Officer. He was previously Chief Medical Officer at Standard Biotools and at SomaLogic where he pioneered the discipline for discovery and validation of predictive, diagnostic and prognostic models using machine-learning applied to large-plex proteomics. 20 such tests were used for drug characterization, safety and efficacy when incorporated in clinical drug trials at Pharma/Biotech and 17 different multivariate tests were validated and translated into regulated healthcare uses. Prior to SomaLogic, Dr. Williams was at Pfizer in the UK and the USA as a clinical triallist in Translational Medicine, and subsequently as VP, Global Clinical Technology. He sat on the National Advisory Council for the National Institute of Biomedical Imaging and Bioengineering, the Executive Committee for the FNIH Biomarkers Consortium, and worked with FDA and PhRMA on developing evidentiary standards for biomarker qualification. Dr. William’s medical training was in London, at Charing Cross and Westminster Medical School, followed by a PhD in medicine/physiology at the same institution and training in Radiology at the University of Newcastle Upon Tyne. Steve is co-inventor on 26 proteomics patents and author/coauthor on multiple foundational proteomics manuscripts.

Justin McAnear

CFO

Mr. McAnear serves as the company’s Chief Financial Officer. He brings over 25 years of operational and financial leadership experience across various sectors and was instrumental in taking 10x Genomics public in 2019, serving as its CFO for over five years. Mr. McAnear served for over 3 years as Tesla’s VP of Worldwide Finance and Operations, supporting landmark initiatives such as the Model X and Model 3 launches and Solar City acquisition. He also held various roles at Apple and J&J earlier in his career and served as a naval officer and aviator for over 9 years.